Open AccessOxidant Stress Impairs In Vivo Reendothelialization Capacity of Endothelial Progenitor Cells From Patients With Type 2 Diabetes Mellitus
Author(s) -
Sajoscha Sorrentino,
Ferdinand H. Bahlmann,
Christian Besler,
Maja Müller,
S. Schulz,
Nina Kirchhoff,
Carola Doerries,
Tibor Horváth,
Anne Limbourg,
Florian P. Limbourg,
Danilo Fliser,
Hermann Haller,
Helmut Drexler,
Ulf Landmesser
Publication year - 2007
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.106.684381
Subject(s) - medicine , rosiglitazone , diabetes mellitus , progenitor cell , in vivo , endocrinology , endothelial progenitor cell , ex vivo , pharmacology , stem cell , biology , microbiology and biotechnology , genetics
Endothelial progenitor cells (EPCs) are thought to contribute to endothelial recovery after arterial injury. We therefore compared in vivo reendothelialization capacity of EPCs derived from patients with diabetes mellitus and healthy subjects. Moreover, we examined the effect of treatment with the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone on oxidant stress, nitric oxide (NO) bioavailability, and the in vivo reendothelialization capacity of EPCs from diabetic individuals.